The haemopoietic system is normally maintained in dynamic equilibrium and when this equilibrium is disturbed the system responds quickly to reestablish it. This presentation will focus upon the behaviour of the haemopoietic progenitor and precursor cells responsible. I shall take erythropoiesis as the example of a cell system committed to the production of a specific end product and consider the pluripotent stem cells from which all haemopoietic cells derive. In the haemoglobinising (and therefore recognisable) erythroid cells there is flexibility in the degree of amplification they can undergo during periods of high demand. In the erythroid precursor cells which cannot be recognised morphologically (but which can be recognised functionally) there is considerable overproduction which is exploited immediately when there is increased demand. There is also an increased production of these precursor cells. The normal production and enormous reserve production capacity is maintained throughout life and would, if necessary, function for several lifespans. The Recently, we have purified a haemopoietic cell growth factor (HCGF) which may represent a "master-control" molecule in haemopoiesis in that the growth factor a) facilitates self-renewal and differentiation of pluripotent stem cells, b) stimulates the committed myeloid progenitor cells and c) "immortalises" granulocyte precursor cells and allows their growth in the absence of stroma. HCGF. acts by modulating energy levels in the haemopoietic cells via its effect on glucose transport. The evolutionary significance of this finding and its relation with leukaemogenesis will be discussed. The avian erythroblastosis virus AEV, causes two diseases in young chickens, erythroblastosis and fibrosarcoma. The oncogene responsible for these diseases is known as erb, and it is capable of producing two gene products, erb B which is primarily responsible for both diseases, and erb A which plays an, as yet undefined, ancilliary role in transformation. Data will be presented on the biosynthesis of the erb B glycoprotein in both wildtype virus transformed cells and cells transformed by temperature-sensitive mutant virus. The results of these experiments show that surface expression of erb B correlates with transformation, and suggests that erb B may be functioning as a growth factor receptor-like molecule to induce the uncontrolled proliferation of the fibroblasts and erythroid cells it transforms.
Studies of the structure of platelet derived growth factor (PDGF) have shown that simian sarcoma virus has acquired cellular sequences which encode a protein almost identical to the precursor of one polypeptide chain of PDGF (Waterfield et al., Nature 304, 35, 1983;  Johnsson et al., to be published). This polypeptide is a growth factor (Deuel et al., 1983 , Science, 221, 1348 In a randomised, double-blind study of 34 patients undergoing treatment with CP for a variety of malignancies, 102 treatment courses were given using D + HDM or placebo (P) + HDM in random sequences as the anti-emetic. The age range was 30-67, mean 56 years. CP at 30mgm-2 was given on 60 courses and lOOmgm-2 on 42 courses. HDM (5 mg kg-1) made up in 500 ml of normal saline was infused in 100 ml aliquots 1/2 h before CP (1 h infusion), and then 2 hourly thereafter. D(20mg) or P (normal saline) was given by i.v. bolus prior to the first HDM dose. 16-18 h after CP, a questionnaire was completed to record the number of dry retches (DR), vomits (V), meals eaten, bouts of diarrhoea and side-effects related to anti-emetic therapy. Nausea (N) was evaluated using a visual analogue scale. Duration of nausea and vomiting was recorded. The results are recorded as % of courses under the following coding: A = free of all N, DR + V; B = free of N; C = free of DR; D = free of V; E= <l day duration N; F= <l day duration V; G = diarrhoea; H = drowsiness. We have studied the patterns of migration of autologous lymphocytes labelled with indium-Ill oxine in normal subjects (Wagstaff et al. (1981) . Clin. Exp. Immunol., 43, 435; Wagstaff et al., 1981, Clin. Exp. Immunol., 43, 443 (McElwain & Powles 1983 , Lancet, 1983 , ii 822). All developed severe leucopenia and thrombocytopenia and needed intensive support. Among previously untreated patients 2/9 are too early to assess, 6/9 recovered well taking a median 28 days (25) (26) (27) (28) (29) (30) (31) (32) (33) Cis-platinum has activity in gastric cancer. We have evaluated the activity of its analogue TNO-6 in gastric and colorectal adenocarcinoma. Twenty two patients entered the study. All had histologically proven disease. Sixteen patients had gastric cancer, six of whom had received previous chemotherapy with F.A.M., and six colorectal cancer three of whom had received previous 5-fluorouracil. All patients had measurable disease. Cells were seeded into 24-well plates and, after 72 h, were exposed to adriamycin or adriamycin plus verapamil for a further 72h followed by a recovery period of 120 h. Cell number at the end of this period was determined by trypsinisation and Coulter counting of the resultant single cell suspension. A decrease in the adriamycin ID50 of at least 5-fold for the two resistant cell lines was observed upon the addition of verapamil with growth inhibition increased from 25% to 75% for G-CCM at 7 x 10-8M adriamycin and from 50% to 90% for G-UVW at 3 x 10-8M adriamycin. Further studies using other drugs are in progress.
A B C D E F G H
These data suggest that for human tumour cells adriamycin resistance is related to differences in drug transport as has been demonstrated in animal models. Furthermore, a potential role for verapamil in circumventing the tumour cell resistance observed clinically is suggested. These compounds have been tested for activity against the M5076 ovarian sarcoma and the TLX5 lymphoma in vivo in mice. Against both tumours, N-methylformamide R1 = Me, R2 = R3 = H, X = O; NMF) was by far the most potent agent of the group. A putative metabolite of NMF, N-(hydroxymethyl)-formamide (R1 = CH2OH, R2 =R3= H, X = 0) had, at most, marginal activity in these tests. In this series, it appears that an N-methyl group is a strong requirement and the formyl group is a lesser requirement for activity. (1 PR, 2 SD) who subsequently responded to low dose AG + HC. In 6 patients who had a prior response to Tamoxifen therapy there were 3 (2PR, 1 SD) subsequent responses to low dose AG+ HC. Toxicity with low dose AG + HC was considerably less than previous experience with higher doses (Harris et al., 1983, Eur. J. Cancer Clin. Oncol., 19, 11) , nausea and vomiting occurring in 3% of patients on the low dose schedule versus 15% with higher dose AG (rash incidence was the same in both low and higher dose groups). Low dose AG produced an objective response rate comparable to conventional dose with considerably less toxicity. Trilostane (T) a steroid agent, is an inhibitor of adrenal enzymes in the rat. We have shown that a combination of (T) 240mg qds and Dexamethasone 0.5mgbd induce remission in metastatic breast cancer (Beardwell et al., 1983, Cancer Chemother Pharmacol., 10, 158). The principle hormonal changes occurring in those patients on (T) alone, were significantly elevated serum concentrations of 170 H pregnenolone, dehydroepiandrosterone sulphate and androstenedoine, with significantly reduced levels of oestrone. After the addition of Dexamethasone, levels of these hormones returned to baseline, with the exception of oestrone, which remained depressed. The response in all patients receiving therapy for >eight weeks was 10/31 PR (32%) and 3/31 (10%) stable disease by UICC criteria. Gastrointestinal side effects were common, vomiting occurring in (24%) and diarrhoea in (11%) and therapy was withdrawn in (18%). Nineteen patients subsequently received (T) 120mgqds with Dexamethasone 0.5mg bd. The incidence of side effects were greatly reduced, but an objective response was observed in only one patient which suggests that the lower dose may be ineffective, although initial results suggest that the hormonal effects on (T) alone are similar for both doses. The mechanism of action of the combination is presently undefined, but the differences in response with the two doses of (T) suggests that the antitumour is not due to Dexamethasone alone. Further studies are in progress to determine the optimum dose and frequency of administration. Significant differences between treated and control patients were seen in those with 1-3 nodes involved (P=0.04), >4 nodes (P=0.02) and also in premenopausal patients (P= 0.02) but not in postmenopausal patients (P=0.13). There was no significant difference in overall survival between the two groups. Side effects were common and included nausea and vomiting (65%), myelosuppression (70%) and alopecia (20%).
We conclude that CMF significantly delays recurrence but, at least, early in the follow up period has no effect upon survival. Activated transforming genes have been found in a number of human tumour DNA's using the NIH/3T3 transfection assay. In most cases the genes detected are members of the cellular ras gene family. The mechanism by which they have been activated in tumour cells has been shown to be a single point mutation resulting in the alteration of an amino acid in the p21 protein product. We have investigated the effect of modifying the normal cellular c-Ha-ras-1 gene by treatment with (±)anti-7,8-dihydroxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo-(a)pyrene (BPDE). pEC, a plasmid containing an insert that carries the c-Ha-ras-l gene, in 10mM tris-HCl, ImMEDTA, ph7.4 (O.5 gjl-l) was treated with various concentrations of BPDE in EtOH (0.5 vol) at 370 for 2 hours. DNA was purified from the reaction mixture, calciumphosphate precipitated and used in an NIH/3T3 transfection assay (200-1000 ng/plate). After 2 weeks the plates were scored for transformed foci. From The availability of the fR series of SV40 transformed breast epithelial cell lines (Chang et al., 1982 , Cancer Res., 42, 2040 gives us a unique opportunity to study how SV40 can be integrated in the DNA of human epithelial cells. DNA mapping experiments using restriction enzymes and southern blot techniques show that one SV40 genome is integrated in these transformed cells and that there is a deletion of up to 100 base pairs in the region coding for large T-antigen. The sites of integration and deletion are coincident and map in the region 4000-4100. The NH2-terminal end of the large T-antigen is intact, a finding consistant with the idea that this region may be essential for transformation (Colby & Shenk, 1982, PNAS, 79, 5189; Clayton et al., 1982, Nature, 299, 59 separated by capillary gas chromatography, detected using a nitrogen detector and quantified by reference to an internal standard, hexaethylphosphoramide. Analytical recoveries were 73.6% and 95.2%, intra-assay variations (s.e.) were 5.6% and 7.5% (n = 12), and inter-assay variations (s.e.) were 8.8% and 12.5% (n=6) for TEPA and thioTEPA, respectively, at concentrations of 50ng ml -1. The limit of sensitivity was 1-5 ng ml-1 for both compounds. The elimination kinetics of thioTEPA were biexponential in 3 of 6 patients and the half-life of the initial phase was greater (range, 1.4-2.5h) than in mice (mean+s.e., 14.0+0.4min). Cancer, 48, 132) .
In this study, we hoped to define the uptake of drug into tumour cells and the intra-cellular fate of the label. Uptake experiments were performed with TLX5 lymphoma using [6-14C-imidazole] CCRG 81010. The rate of uptake was rapid and temperature dependent (equilibrium within 1 min at 37°C and 6 min at 4°C), directly proportional to drug concentration and independent of metabolic inhibitors. A cell: medium distribution ratio of unity was achieved suggesting a passive diffusion process. No difference in uptake was seen between drug sensitive and resistant cells.
Radioactivity was found to be progressively accumulated into acid-insoluble material. Acid hydrolysis followed by HPLC separation of DNA/RNA components showed that the radioactivity was associated solely with adenine and guanine. Over a 24 h period about 80% of the CCRG 81010 in the medium was converted to 5-aminoimidazole-4-carboxamide (AIC). Non-radiolabelled AIC suppressed the incorporation of radioactivity into nucleic acids but had no effect on the initial rate of uptake of CCRG 81010. It was concluded that all the radioactivity in DNA and RNA was due to the salvage of AIC for de novo base synthesis. Six human tumour xenografts grown in nude mice were tested in vivo against MTX. Only one of them, an acute myeloid leukaemia grown as a solid tumour, was sensitive. Groups of xenograft-bearing mice were then given MTX 100mg kg-1 i.p. and the dihydrofolate reductase (DHFR) activity of the cytosol of the tumours was determined at intervals. This apparent enzyme activity rose between 1.7 and 12.0-fold in the resistant tumours, usually peaking at 3-4 days after treatment, but fell in the sensitive tumour to 0.3 of the pretreatment value. These findings concur with studies on patients with acute leukaemia (Bertino, et al., 1977, Cancer Treat. Rep. 61, 667 The levels of THB and its oxidation products 7,8-dihydrobiopterin (DHB) and biopterin (B) were measured in whole rat brain using HPLC, acidiodine oxidation and alkaline-iodine oxidation. In adult male control rats (10) total biopterins were 222.4+45.8 (mean+s.d.)pmolg-1 wet weight, of which 95.3% was THB, 2.8% was DHB and 1.9% was B. Four hours after an oral dose of MTX
(1 mg kg-1) (6 rats) total brain biopterins were increased to 351.9 +134 pmol g -1 wet weight (P<0.01) and the percentage distribution of THB, DHB and B was unchanged. With an oral dose of 100mg kg-1 (6 rats), after total brain biopterins were similar to controls (188.6 + 34.3 pmol g-wet weight) but the distribution of the biopterins was significantly altered. Percent THB was 76.7 (P<0.01 compared to control), DHB was 18.7 (P<0.025) and %B was 4.6 (P<0.01). 
CB3717 (N-(4-(N-((2-amino-4-hydroxy-
is an antifolate inhibitor of thymidylate synthetase currently undergoing clinical evaluation at a number of centres in the UK. Hepatotoxicity is the most prevalent side-effect observed with CB3717; 50% of patients develop elevations of plasma alanine transaminase (ALT) to over twice the upper limit of normal. In mice CB3717 also produced elevations of plasma ALT which were maximal 6 h after a single i.p. dose, returning to normal by 24 h. After 100 mg kg-1 CB3717, plasma ALT levels of 2-30 x control were observed whilst at 300mg kg-1 ALT elevations of 28-50 fold were produced. The administration of thymidine (2 x 500mg kg-1), 5-methyltetrahydrofolate (1 or 3 x lOmgkg-1) or folinic acid (1 or 3 x lOmgkg-1) did not reduce CB3717 hepatotoxicity in mice. As thymidine and folinic acid can abolish the antitumour activity of CB3717 it is unlikely that hepatotoxicity is mediated through inhibition of liver thymidylate synthesis. Although CB3717 can produce a 40% depletion of liver total nonprotein thiols the administration of N-acetyl cysteine (500mgkg-1) did not reduce CB3717 hepatotoxicity. Studies with structurally related quinazolines showed that equimolar doses of the N10-ethyl and N10-unsubstituted analogues produced no hepatotoxicity. However, pharmacokinetic studies demonstrated that plasma quinazoline levels following the two analogues were considerably lower (<I/Oth) than those observed after CB3717. This suggests that the liver damage produced by CB3717 may limit its hepatic clearance. Furthermore, CB3717 hepatoxicity is apparently related to the N10-prop-2-ynyl substituent.
Although the SGD values produced by the combinations are all greater than predicted for a purely additive effect, these differences do not reach statistical significance. It aryldiazonium ion to the carbinolamine, RNHCH2OH, generated in situ from formaldehyde and the alkylamine. Hydroxymethyltriazenes react with acetic anhydride in pyridine to afford the acetoxymethyltriazenes, ArN = N-NRCH2OAc, and with benzoyl chloride in pyridine to yield the benzoates, ArN = N-NR.CH2OCOPh. These derivatives are suitable prodrugs since they should not require metabolic oxidation to exert a cytotoxic effect. The acetates and benzoates react with methanol to give the methoxymethyltriazenes, ArN = N-NRCH2OMe, which may be suitable prodrugs through 0-demethylation. The antitumour activity of a hydroxymethyl-, acetoxymethyl-, and methoxymethyltriazene has been compared with the activity of the corresponding dimethyl-and monomethyltriazenes (see Table) . analysis of the amine, employing low wavelength UV detection and have subsequently investigated its production and distribution in mice, 3 h after a single i.p. dose of 650mgkg-' benznidazole. This dose produces plasma benznidazole concentrations of 120-130 jug ml-1 with tumour/plasma ratios of 80-100% in C3H mice bearing RIF-I and KHT tumours, and BALB/c mice bearing EMT6 tumours. Plasma amine concentrations were very low (0.3-0.7 yg ml -1) with similarly low amounts present in the 2 C3H mouse tumours (0.3-1.4,jgg-1). Higher concentrations were detected in EMT6 tumours (4.lgug-1+0.33 SE, n=16) suggesting that this tumour may be more hypoxic or have greater nitroreductase activity than RIF-1 and KHT tumours. Livers from these C3H mice contained very high levels of amine (51 jig g 1 + 2.5, n = I 1) implicating this tissue as a major site of nitroreduction. Both strains of mice excreted -3% of administered benznidazole as the amine in the 24 h urine, with a further 4% as the parent compound. We have also demonstrated in vitro nitroreduction of benznidazole using whole liver homogenates. The reaction is inhibited by oxygen and has an absolute requirement for reduced nicotinamide adenine dinucleotides, particularly NADPH. In summary, nitroreduction of benznidazole has been shown to occur in mouse tissue in vivo and in vitro, and its clinical significance is under investigation. Benznidazole is a lipophilic analogue of misonidazole currently undergoing phase I clinical trial as a chemosensitizer, in combination with the nitrosourea CCNU. Reductive metabolism of nitroimidazoles to their amine derivatives has been implicated in the mechanism of cytotoxicity and chemosensitization, possibly through the production of chemically reactive intermediates. To study benznidazole nitroreduction we have developed a reverse-phase paired -ion HPLC technique for the Department of Radiobiology, Velindre Hospital, Cardiff, UK.
A human breast tumour xenograft, HX99 (donated by A.C. Jones, Royal Marsden Hospital, London), implanted in immune suppressed female CBA mice (Steel, 1978 et al., Br. J. Cancer, 37, 224) , has been used to study the in vivo chemosensitization of melphalan (MEL) by misonidazole (MISO). Mice bearing tumours of approximately 8mm diameter were injected i.p. with drugs delivered in 0.01 ml-g. MEL was used in doses of up to and including the LD10 value (14mg-1kg). MISO was administered as total doses of 1 mg-g, 0.5 mg-1 g, 0.25 mg-1 g, and 0.1 mg-1 g. Tumours were excised after 20 h and cell kill determined by a soft agar assay (Courtenay & Mills, 1978, Br. J. Cancer, 37, 261) . MEL at 14mg -kg gave a 40% cell kill and MISO alone at I mg-I g gave no significant cell kill. However, when combined chemosensitization was seen, for example, with total doses of 1 mg'-I g and 0.5mg-1g, a cell kill of greater than 96% was produced. We previously showed that misonidazole (MISO) reduced the clearance of CCNU in mice resulting in a selective increase in tumour CCNU concentration, and we proposed this to be the major mechanism of chemosensitisation and therapeutic gain (Lee & Workman, 1983, Br. J. Cancer, 47, 659) . Since both MISO and CCNU undergo extensive metabolism in the liver, the reduced clearance of CCNU is likely to be due to the effect of MISO on hepatic CCNU metabolism. We have therefore studied the effect of a range of nitroimidazoles of varying chemosensitisation activity (Workman & Twentyman, 1982, Br. J. Cancer, 46, 249) on the metabolism of CCNU by mouse liver microsomes. Microsomes were prepared by standard subcellular fractionation. CCNU and its metabolites were separated and individually quantitated using a reversed-phase HPLC method. In the presence of 02. glucose-6-phosphate, glucose-6-phosphate dehydrogenase and NADP, CCNU is metabolised to at least 5 different ring-monohydroxylated active derivatives. Values of Km and Vmax for the formation of the major metabolite cis-4-hydroxy-CCNU were 0.028 mM and 2.08 nmoles min-1mg-1 microsomal protein respectively. MISO inhibits the rate of formation of the metabolites with an ID50 of 6.4 mM. Values of ID50 for the various nitroimidazoles were in the order: benznidazole < RoO7-1902 < MISO < RoO5-9963 < SR-2508. At concentrations similar to the achieved plasma concentrations in mice given 2.5 mmoles kg-1, the extent of inhibition of CCNU metabolism was 80% for benznidazole, 65% for RoO7-1902, 33% for MISO, and 0% for RoO5-9963 and SR-2508 . Therefore these data show that the order of effectiveness of nitroimidazoles in inhibiting microsomal CCNU metabolism directly correlates with the order of efficacy for enhancement of tumour response and provide further evidence for the pharmacokinetic mechanism of chemosensitisation.
We have investigated the response of exponentially growing EMT6 tumour cells, in vitro, to treatment with hyperthermia (1 h at 43°C) prior to treatment with Adriamycin (ADM) (0-20pg ml-1 for 1 h at 37°C). Relative intracellular ADM concentration was measured by flow cytometry (FCM) and compared with survival data (clonogenic assay). FCM demonstrated that control cells accumulated twice as much ADM as preheated cells. However, FCM measurements of ADM in cells permeabolised after heat treatment but before drug administration indicated that hyperthermia did not significantly alter the amount of ADM that could be accumulated once the membrane barrier had been removed. Survival data showed that preheated cells had a higher surviving fraction than control cells, 0.3 at 3 ig ml-l compared to 0.007 for unheated cells, as predicted by FCM. However, comparing surviving fraction data with intracellular drug measurement revealed that preheated cells were less sensitive to a given internal ADM concentration (at an FCM measurement of 100 fluorescence units preheated cells have a surviving fraction of 0.1 compared to 0.01 for non-heated cells.) This suggests that the initial observed difference in surviving fraction is not due simply to a difference in accumulation of ADM but also a change in the intrinsic sensitivity of cells that have been subject to preheating at 43°C. We conclude therefore, in EMT6 cells, preheating for 1 h at 43°C protects the cell from ADM by reducing the amount of drug entering the cell, apparently by altering membrane permeability, and also protects the cell by reducing its sensitivity to the drug that does pass through the membrane. Three-dimensional spheroids can be regarded as good in vitro models for solid tumours. It has been suggested that cell to cell contact can be an important mediator of the response of spheroids to damage caused by radiation and cytotoxic drugs. We have been assessing the role of contact effects in the radiation and drug response of V79 and human tumour spheroids (ME/MAR small cell lung carcinoma cell line and HX 117 -melanoma xenograft). This report describes a comparative study of the ultrastructural and cytotoxic effects of the intercalating agents, adriamycin and mAMSA. Electron microscopic examination shows that V79 spheroids are characterized by the possession of desmosome type junctions as well as tight junctions, HX 117 have many fewer desmosome type junctions, and ME/MAR spheroids lack any recognizable junctions whatsoever. Both adriamycin and mAMSA cause degeneration of cell membranes within spheroids at doses that do not cause any recognizable nuclear aberrations. The membrane effects are most marked near the outside of the spheroid and are not apparent towards the centre, the region containing the quiescent cells and hypoxic cells. Drug priming is a phenomenon where a small "priming" dose of a cytotoxic compound will protect patients from the acute toxicity of a much higher dose of the same or a different compound. In the present study we have investigated the relationship between priming as protection against cyclophosphamide (CP)-induced-myelotoxicity, and reduced glutathione (GSH) and glutathione-Stransferase (G-S-T) levels in the mouse bone marrow.
CBA mice survived an otherwise lethal dose of CP (350mgkg-1) when "primed" with an injection of 75mg kg-1 CP five days prior to the lethal dose. Our data demonstrate that a lethal dose of CP caused a dramatic depletion of GSH in the bone marrow and that the extent of this depletion was limited by a priming dose of CP. Although a priming dose of CP caused an initial depletion of GSH, the GSH content of the marrow in primed animals was 180-290% that of controls at day 5. The time course of intracellular glutathione levels mirrored the susceptibility of the mice to a lethal dose of cyclophosphamide. This was also the case for glutathione S-transferases which on day 5 were dramatically increased over control values (252% control).
We postulate that survival of primed animals injected with an otherwise lethal dose of CP five days after priming is due, at least in part to the high levels of GSH and G-S-T detected in the bone marrow. That is, that the "overshoot" of GSH and G-S-T allows for the removal of the fatally myelotoxic products of cyclophosphamide metabolism through conjugation with GSH. Gamma glutamyl transpeptidase (GGT), a membrane bound glycoprotein consisting of 2 heterologous subunits, exists as several isosymes, varying in their degree of glycosylation. Enzyme levels are high in fetal rat liver, while the very low activity in adult liver is confined mainly to bile duct epithelia. However, exposure to a wide range of carcinogens leads to the formation of preneoplastic foci of hepatocytes, many of which are GGT positive.
To investigate the role of GGT in carcinogenesis we are studying the molecular events in the formation of the enzyme. Total RNA has been isolated by guanidinium isothiocyanate extraction from rat tissues rich in GGT, i.e. kidney, aflatoxin B1 (AFB1) fed-liver and a tumour cell line derived from such a liver. In vitro translation of RNA using the rabbit reticulocyte lysate system and immunoprecipitation of specific translation products using anti-kidney GGT polyclonal antibody** and protein A have been used to identify the non-glycosylated pre-protein form of the enzyme. RNA preparations have been enriched for the mRNA of interest by fractionation on 5-20% sucrose gradients and by oligo-dT-cellulose chromatography.
Such enriched mRNA preparations have been used to synthesize cDNA, which in turn can be used as a probe to investigate the effect of carcinogens on mRNA populations and transcription of the gene(s) for GGT. 5-azacytidine (Aza-C) is known to inhibit methylation in newly synthesized DNA and to induce gene activation. It has been used in the experimental treatment of acute leukaemia, thalassaemia and sickle cell anaemia. This report shows that it is also a carcinogen. Young adult male F344 rats were given Aza-C 2.5-l0mgkg -i.p. in saline twice weekly for 9 months and examined 9 months later. About 30% of the rats died before the end of the experiment and could not 6e evaluated. Of the survivors, the number of rats with tumours/number of rats examined were 17/20. Controls 0/12. The tumour types were Leydig, Sertoli and interstitial cell testis (10); invasive squamous cell skin (3); adeno-carcinoma of lung (1) and reticuloendotheliosis (1). A follow-up experiment using Zza-C analogues has been initiated. The cytotoxicity of Aza-C and analogues (all at 10 -4M) was examined using a 24 h viability assay with normal rat hepatocytes. Results (% survival/controls) were (av. of 6 expts. = cytosine 85; cytidine 77; 5-fluorocytosine 69; 5-fluorocytidine 47; 5-fluoro-2-deoxycytidine 62; 5-azacytidine 32; 5-aza-2-deoxycytidine 63; 5,6-dihydro-5-azacytidine 50; 6-azacytidine 67; pseudoisocytidine 70. Tetrahydrouridine, a deamination inhibitor, was not toxic and did not increase the toxicity of any of the above analogs at 10-6-10-2M. Thus, Aza-C is a carcinogen in the rat. Aza-C, 5-fluorocytidine and 5,6-dihydro-Aza-C are toxic in vitro. The deoxyribose analogues are less toxic than the ribose analogues, suggesting that cytotoxicity may not be mediated solely through DNA. In current in vivo expts. a similar toxicity is observed as weight loss with Aza-C and fluorocytidine but not with equimolecular amounts of their deoxy analogues. In an attempt to assess the sensitivity of human skin to polycyclic hydrocarbon carcinogenesis, the metabolism and activation of hydrocarbons in susceptible and resistant rodent skin in vivo and in vitro is being examined and compared with that occurring in human skin in short-term organ culture. Chrysene, an environmental contaminant, is weakly carcinogenic to mouse skin and is converted by human and mouse skin in organ culture and by mouse skin in vivo to chrysene-1,2-, 3,4-and 5,6-dihydrodiols: A chrysene-triol that is believed to be 9-hydroxychrysene 1,2-diol was also found in some experiments. Chrysene-1,2-diol is a precursor of both the "bay-region" diol-epoxide, chrysene-1,2-diol 3,4-oxide, and a triol-epoxide in mouse skin; chrysene-1,2-diol is also more active than the parent hydrocarbon as a tumour initiator in this mouse tissue. The stereochemistry of the 1,2-diol and of the other diols that are formed as metabolites of chrysene by mouse skin was investigated by normal phase hplc using columns that contained an optically-active stationary phase and it was found that (-)-enantiomers were formed almost exclusively. When chrysene-treated mouse skin was maintained in short-term organ culture, dihydrodiols were released into the medium, however, the enantiomeric purity of the 1,2-diol did not vary as it accumulated over a 40h incubation period. Levels of the chrysene-triol appeared to reach equilibrium after 20-24h. The formation and the enantiomeric purity of the chrysene-triol that is formed by metabolism from optically-pure samples of the chrysene-1,2-diol is being examined together with the hydrocarbon-deoxyribonucleoside adducts that are formed in human skin that has been treated in short-term organ culture with chrysene. It is well known that in many tissues cancer incidence is directly proportional to the dose of carcinogen. This dose-response relationship is substantially modified by the frequency of dosing.
F344 rats were given 150, 300 or 600mg of the bladder carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in 3, 6, 9 or 12 weekly aliquots. The incidence of bladder tumours and hyperplasias was assessed at 1, 13, 26 and 52 weeks post-dosing. With equal numbers of aliquots there was a clear dose-related response, but for each total dose more and smaller aliquots produced a greater response than fewer larger aliquots. The frequency with which the tissue was exposed to BBN was more important than the total dose; for example, tumour incidence after 600mg split into 3 doses was lower than after 300mg split into 6 or 150mg split onto 12 aliquots.
These results emphasise the potential danger of multiple low dose exposure to carcinogens when attempting to assess risk factors. The results also indicated that the urothelial hyperplasias were precursors of the tumours.
Binding of benzo (a) The streptococcal immunopotentiator OK432 has been found to enhance the natural killer (NK) activity of human peripheral blood mononuclear cells (PBMC) in vitro (Wahangi et al., 1982, JNCI, 69, 807 Fibroblasts derived from apparently normal skin of each of these patients were examined and also showed the same patterns of migration.
The implications of this finding in relation to the systemic nature of malignancy will be discussed. clones being markedly more resistant to drug treatment than diploid clones. In the present study RIF-1 clones growing in log phase culture were treated for 1 h at 37°C with appropriate concentrations of nitrogen mustard, aniline mustard and chlorambucil, and with nitrosoureas BCNU, MeCCNU and chlorozotocin, in order to evaluate whether or not the different physiochemical and biological activities of these agents would affect the patterns of drug sensitivity described above. Irrespective of the different lipophilicities and transport mechanisms of the nitrogen mustards used in the present study, RIF-1 clones showed the same pattern of sensitivity when exposed to either melphalan, nitrogen mustard, aniline mustard or chlorambucil. Similarly RIF-1 clones when exposed to BCNU, MeCCNU and chlorozotocin showed the same pattern of sensitivity as that observed for CCNU treatment. These data suggest (a) that the variation in the sensitivity of RIF-1 clones to treatment by the nitrogen mustards is unlikely to reflect differences in either membrane permeability or in drug transport mechanisms within the cells (b) that the ploidy dependent nitrosourea responses shown by RIF-1 clones similarly do not reflect differences in membrane permeabilities or in cell sensitivities to relative alkylation versus carbamoylation. Furthermore, it is likely that a common mechanism may predominantly govern response to the different nitrosoureas, whereas a different common mechanism may govern response to the nitrogen mustards.
Nitrogen mustard selectively inhibits rubidium influx into murine L1210 leukaemia cells The interaction of antineoplastic drugs with the plasma membrane may contribute or be causative to their cytotoxicity. It has been shown that nitrogen mustard (HN2) inhibited the net accumulation of 86Rb+ (a potassium congener) into mouse plasmacytoma cells (Baxter et al., 1982 , Biochem. Pharmacol., 31, 1773 . This inhibition was suggested to result from the inactivation of the enzyme Na+K+ATPase, which plays an important role in the control of cell proliferation. In order to define more fully these observations on net 86Rb+ accumulation, the effects of HN2 (10- (Simms et al., 1980, Cancer Res., 40, 4356) with or without 2.5% foetal calf serum, as well as specimens directly from the clinic. In a comparison of two soft agar cloning assays for a wide range of specimens we found a higher plating efficiency in the method of Courtenay & Mills, (Br. J. Cancer., 1978, 37, 261) than in the double-layer technique described by Carney et al., 1980 , (Cancer Res., 40, 1820 . In addition the colonies were larger and easier to isolate using the former technique, probably due to the repeated medium replenishment involved. Varying the conditions of the Courtenay assay produces different effects for different cell types. For a small cell lung cancer line, the presence of rat red cells in the agar plug was a critical factor whereas it was less important for an adenocarcinoma cell line and a large cell anaplastic cell line. In general, growth in atmospheres containing 5% or less of oxygen was better than in 20% oxygen. Addition of irradiated feeder cells was of variable value. These factors are closely interrelated and do not operate as independent variables. Two human ovarian cell lines, PEOI and PEO4, have been established from ascitic fluid samples of a patient before and after the development of clinical resistance to a combination of 5-fluorouracil, chlorambucil and cis-platinum. The two cell lines exhibited certain similarities but also some significant differences. Both lines contained vesicular nuclei with prominent and occasional multiple nucleoli and vacuolated cytoplasm. "Signet ring" mucin containing cells were also present. A significant number of rearranged chromosomes were observed in cell lines PEOI and PEO4.
Abnormal chromosomes in common were 3, 9, 13 and 22. PEO4 had a chromosome 8 and 17 not identifiable in PEOl. Significant differences between PEOl and PEO4 -in their doubling times (33h vs 24h), plating efficiency in plastic (0.8% vs 5.7%) and in agar (0.1% vs 4.0% early passage, 4.6% vs 14.0% later passage), contact inhibition and sensitivity to trypsin treatment were observed. In addition glutathione and glutathione Stransferase activities (components intimately involved with the deactivation of alkylating agents) were approximately 2-5 fold higher in PEO4 than PEOI. Mean glutathione concentrations were 0.8 and 5.9nmol 106 cells-' and transferase activities were 35 vs 159 nmol conjugate formed min -1106 cells-. Preliminary experiments indicate a much higher susceptibility of PEO1 to cisplatinum than PEO4. For drugs which require metabolic activation the clonogenic Courtenay assay has been modified to incorporate an activating system. In this system cyclophosphamide was highly active against PEO4. We have reported several times in the past on our investigations related to the search for an aryltriazene as a suitable second-generation analogue of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, Dacarbazine). Our original approach, which included a detailed structure-activity study (Connors et al., 1976, Biochem. Pharmacol., 25, 241) , was aimed at overcoming problems which reputedly arose from the photodecomposition of DTIC. As this is no longer regarded as a problem, though not losing sight of this objective, we have now become interested in the response of astrocytomas to these compounds. Grade IV astrocytoma xenografts grown as s.c. flank implants in immune deprived mice are sensitive to a number of clinical drugs, e.g. nitrosoureas, procarbazine, DTIC and a number of aryltriazenes, whereas the Grade III tumours show relatively little response. We have chosen one of these sensitive Grade IV astrocytomas (508) for a more detailed study. When implanted intracerebrally this tumour is sensitive only to nitrosoureas and aryltriazenes, compounds which meet Levin's criteria for compounds to cross the blood-brain barrier (J. Med. Chem., 1980, 23, 682) . The flank implant of this tumour is sensitive to a range of aryldialkyltriazenes resulting in the "cure" of a number of implants. Testing of these compounds in the intracranial system will assist the choice of a suitable second-generation triazene to recommend for preclinical toxicology. A human tumour xenograft programme designed to study chemotherapeutic agents has involved the transplantation of 75 different tumours into athymic mice over a period of 4 years. Some of these tumours have been passaged more than 20 times. During this period two tumours, an oat cell carcinoma of the lung and an ovarian carcinoma showed striking changes in their biology. There was a shortening of the passage interval from 259 days to 17 days and 274 days to 20 days respectively (tumours were passaged when they had reached a mass of 1-2g), the karyotype changed from human to mouse, the LDH isoenzymes of the tumour developed mouse characteristics and the tumours became invasive with ulceration of the skin and metastases to regional lymph nodes and the lung, which is a feature rarely seen in xenografts. Histological examination of the tumours over three passages showed a gradual replacement of the
